Global pharma is back in the political spotlight, as US pressure on drug prices abroad collides with European cost controls and fresh trade tensions. For investors, this mix of policy risk and pricing shifts could change how large pharmaceutical stocks are viewed, especially those with significant US and European exposure. This article looks at three large-cap global pharmaceutical companies from our screener that appear especially exposed to the latest headlines, and explains why some investors may see opportunity while others may prefer to stay cautious.

GSK (LSE:GSK)

Overview: GSK is a UK based global pharmaceutical company that develops and manufactures vaccines, specialty medicines in areas like oncology, respiratory and HIV, and general medicines for common chronic and infectious diseases.

Operations: GSK generates all of its £32.8b in revenue from its Commercial Operations segment.

Market Cap: £80.3b

GSK sits at the center of the current drug pricing debate, with a large UK, US and European footprint, a sizeable vaccines and specialty medicines portfolio, and a pipeline that includes recent approvals like Utebzi for complicated UTIs and multiple late stage programs in oncology and immunology. US oriented manufacturing and supply chain work suggest the company is preparing for possible tariff and pricing shifts. At the same time, high debt, legal payouts linked to legacy products and future patent expiries mean the path is not risk free. How those trade offs stack up, especially against GSK’s current valuation signals, is where the real story starts.

GSK’s mix of high stakes drug pricing exposure, vaccines strength and legal overhangs can make the story feel incomplete, so it pays to see how those threads connect in the 4 key rewards and 3 important warning signs

Viatris (VTRS)

Overview: Viatris is a global healthcare company that supplies branded, generic, complex generic drugs and biosimilars across a wide range of diseases, from cardiovascular and diabetes to oncology and respiratory conditions, reaching patients in more than 160 countries. It also supports treatment with services like diagnostic clinics, education and digital tools to help patients manage their health.

Operations: Viatris generates US$8.7b in revenue from Developed Markets, US$2.5b from Greater China, US$2.2b from Emerging Markets and US$1.2b from JANZ.

Market Cap: US$19.4b

Viatris stands out in large cap pharma because it combines a global generics powerhouse with a growing branded and complex drug portfolio that is closely tied to current debates on tariffs and drug pricing. The company serves about 1 billion patients a year and is active in US and European markets that could benefit if higher overseas prices offset pressure at home. It is also pushing late stage products like Nefecon for IgA nephropathy and fast acting meloxicam for pain. At the same time, Viatris is working through a history of losses, heavy use of external debt and the regulatory and pricing pressure that typically comes with generics. The main question for investors is how that balance looks once factors such as its low P/S, current earnings outlook and tariff positioning are taken into account.

Viatris looks like a global workhorse whose low P/S and tariff exposure could be masking a more interesting story around pricing power and resilience, and the analysis report for Viatris hints at one detail that could change how you see it

Johnson & Johnson (JNJ)

Overview: Johnson & Johnson is a global healthcare company that researches, develops and sells prescription medicines across areas like oncology, immunology and cardiovascular disease, alongside a MedTech business that supplies surgical tools, orthopedic products and vision care devices used in hospitals and clinics worldwide.

Operations: Johnson & Johnson generates about US$61.95b in revenue from its Innovative Medicine segment and US$34.41b from MedTech.

Market Cap: US$633.19b

Johnson & Johnson offers a mix that many investors look for in large pharma, with a broad drug and device portfolio, high net margins of 21.8% and a 64 year record of raising its dividend, set against real issues like high debt, litigation exposure and pressure from loss of exclusivity on products such as Stelara. The company is leaning into US policy shifts with a US$55b investment plan to manufacture all advanced medicines used in the US domestically. This could matter if tariffs and foreign price reforms reshape global drug economics. For a stock already trading on a P/E around 30x, how those policy tailwinds, pipeline assets and legal and funding risks net out is the key question investors need to answer.

Johnson & Johnson’s mix of high margins, MedTech scale and a P/E around 30x suggests the stock might be pricing in more than many realize. The 3 key rewards and 1 important warning sign could reveal what the market is quietly bracing for.

The three large cap stocks in this article are only a starting point, as the full Large-cap Global Pharmaceutical Companies screener surfaces 10 more companies with equally compelling pharma narratives that many investors have not looked at closely yet. Use Simply Wall St to identify and analyze the specific catalysts, policy angles, and business drivers that matter to you so you can focus on the highest conviction ideas in this theme.

Take Control of Your Investment Journey

If Viatris or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others?

Some stocks are already building breakout momentum while most investors are still looking the other way. Consider these fresh ideas that may be under the radar for now, before the window drops.

• Spot cash generative companies before they start gaining wider attention by scanning the 9 high quality undervalued stocks that focuses on durable balance sheets and earnings support.
• Identify steady income opportunities as yields move around using the curated 3 dividend fortresses to see which companies currently combine resilience with 5%+ payouts.
• Track developments in automation momentum through the hand picked 29 robotics and automation stocks where industrial, medical and consumer robotics stocks may still be under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.